CONTEXT: Resistance to TSH (RTSH) is a condition of impaired responsiveness of the thyroid gland to TSH, characterized by elevated serum TSH, low or normal thyroid hormone levels, and hypoplastic or normal-sized thyroid gland. OBJECTIVES: The aim of the study was to evaluate the clinical course and the genotype-phenotype relationship of RTSH caused by two different TSH receptor (TSHR) gene mutations in a consanguineous population. PATIENTS AND METHODS: We conducted a clinical and genetic investigation of 46 members of an extended family and 163 individuals living in the same town. In vitro functional studies of the mutant TSHRs were also performed. RESULTS: Two TSHR gene mutations (P68S and L653V) were identified in 33 subjects occurring as homozygous L653V (five subjects), heterozygous L653V (20 subjects), heterozygous P68S (four subjects), and compound heterozygous L653V/P68S (four subjects). With the exception of one individual with concomitant autoimmune thyroid disease, all homozygotes and compound heterozygotes presented with compensated RTSH (high TSH with free T(4) and T(3) in the normal range). Only nine of 24 heterozygotes had mild hyperthyrotropinemia. The L653V mutation resulted in a higher serum TSH concentration and showed a more severe in vitro abnormality than P68S. Haplotype analysis predicted a founder of the L653V six to seven generations earlier, whereas the P68S is older. Cross-sectional and prospective longitudinal studies indicate that TSH and T(4) concentrations remain stable over time. CONCLUSIONS: High frequency hyperthyrotropinemia in an Israeli Arab-Muslim consanguineous community is attributed to two inactivating TSHR gene mutations. Concordant genotype-phenotype was demonstrated clinically and by in vitro functional analysis. Retrospective and prospective studies indicate that in the absence of concomitant autoimmune thyroid disease, elevated TSH levels reflect stable compensated RTSH.
CONTEXT: Resistance to TSH (RTSH) is a condition of impaired responsiveness of the thyroid gland to TSH, characterized by elevated serum TSH, low or normal thyroid hormone levels, and hypoplastic or normal-sized thyroid gland. OBJECTIVES: The aim of the study was to evaluate the clinical course and the genotype-phenotype relationship of RTSH caused by two different TSH receptor (TSHR) gene mutations in a consanguineous population. PATIENTS AND METHODS: We conducted a clinical and genetic investigation of 46 members of an extended family and 163 individuals living in the same town. In vitro functional studies of the mutant TSHRs were also performed. RESULTS: Two TSHR gene mutations (P68S and L653V) were identified in 33 subjects occurring as homozygous L653V (five subjects), heterozygous L653V (20 subjects), heterozygous P68S (four subjects), and compound heterozygous L653V/P68S (four subjects). With the exception of one individual with concomitant autoimmune thyroid disease, all homozygotes and compound heterozygotes presented with compensated RTSH (high TSH with free T(4) and T(3) in the normal range). Only nine of 24 heterozygotes had mild hyperthyrotropinemia. The L653V mutation resulted in a higher serum TSH concentration and showed a more severe in vitro abnormality than P68S. Haplotype analysis predicted a founder of the L653V six to seven generations earlier, whereas the P68S is older. Cross-sectional and prospective longitudinal studies indicate that TSH and T(4) concentrations remain stable over time. CONCLUSIONS: High frequency hyperthyrotropinemia in an Israeli Arab-Muslim consanguineous community is attributed to two inactivating TSHR gene mutations. Concordant genotype-phenotype was demonstrated clinically and by in vitro functional analysis. Retrospective and prospective studies indicate that in the absence of concomitant autoimmune thyroid disease, elevated TSH levels reflect stable compensated RTSH.
Authors: C Govaerts; A Lefort; S Costagliola; S J Wodak; J A Ballesteros; J Van Sande; L Pardo; G Vassart Journal: J Biol Chem Date: 2001-04-18 Impact factor: 5.157
Authors: F Libert; A Lefort; C Gerard; M Parmentier; J Perret; M Ludgate; J E Dumont; G Vassart Journal: Biochem Biophys Res Commun Date: 1989-12-29 Impact factor: 3.575
Authors: N de Roux; M Misrahi; R Brauner; M Houang; J C Carel; M Granier; Y Le Bouc; N Ghinea; A Boumedienne; J E Toublanc; E Milgrom Journal: J Clin Endocrinol Metab Date: 1996-12 Impact factor: 5.958
Authors: Marc-Olivier Turgeon; Tanya L Silander; Denica Doycheva; Xiao-Hui Liao; Marc Rigden; Luisina Ongaro; Xiang Zhou; Sjoerd D Joustra; Jan M Wit; Mike G Wade; Heike Heuer; Samuel Refetoff; Daniel J Bernard Journal: Endocrinology Date: 2017-04-01 Impact factor: 4.736
Authors: S Acar; S Gürsoy; G Arslan; Ö Nalbantoğlu; F Hazan; Ö Köprülü; B Özkaya; B Özkan Journal: J Endocrinol Invest Date: 2021-11-15 Impact factor: 4.256
Authors: S Moia; M Godi; G E Walker; M Roccio; P Agretti; M Tonacchera; R Berardi; S Bellone; F Prodam; M Giordano; G Bona Journal: J Endocrinol Invest Date: 2013-04-08 Impact factor: 4.256